Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

inVentiv Health Clinical

CCC US unveil new multiplatform content group

Group intends to combine storytelling with scientific expertise

- PMLiVE

Pfizer’s RA drug tofacitinib tops methotrexate in phase III

Trial results back drug as major new treatment in rheumatoid arthritis

- PMLiVE

Postcards from China

Part two: The value of innovative medical education in China

Pfizer forms branded generics sales alliance in China

Forms joint venture with local company Hisun

- PMLiVE

AstraZeneca forges CRO alliance to bring biologic to China

MedImmune Subsidiary forms joint venture with WuXi

- PMLiVE

Pfizer’s Andrew Thomas takes up UK comms agency role

Joins London-based Red Door Communications as head of international

Pfizer gets US approval for leukaemia drug Bosulif

FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia

- PMLiVE

Pfizer’s Inlyta gets EU approval for advanced kidney cancer

Available as second-line therapy after treatment with pharma firm's own Sutent

- PMLiVE

Merck Serono spins off biomarker specialist

Led by Jérôme Wojcik, Quartz Bio will operate as a contract research organisation

- PMLiVE

Pfizer dealt another blow as Torisel fails kidney cancer trial

Results are another setback in company's bid to extend the indications for its mTOR inhibitor

- PMLiVE

End of the line for intravenous bapineuzumab in Alzheimer’s

Negative trial results for Pfizer and Johnson & Johnson to concede defeat

- PMLiVE

Pfizer sells Kent R&D centre to property consortium

Discovery Park Ltd takes over site 18 months after US pharma firm announced plans to exit it

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links